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Head and neck cancer is one of the most frequent malignances worldwide. Despite the site-specific mul-
timodality therapy, up to half of the patients will develop recurrence. Treatment selection based on a
multidisciplinary tumor board represents the cornerstone of head and neck cancer, as it is essential for
achieving the best results, not only in terms of outcome, but also in terms of organ-function preservation
and quality of life. Evidence-based international and national clinical practice guidelines for head and
neck cancer not always provide answers in terms of decision-making that specialists have to deal with
in their daily practice. This is the first Expert Consensus on the Multidisciplinary Approach for Head
and Neck Squamous Cell Carcinoma (HNSCC) elaborated by the Spanish Society for Head and Neck
Cancer and based on a Delphi methodology. It offers a number of specific recommendations based on
the available evidence and the expertise of our specialists to facilitate decision-making of all health-
care specialists involved.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction and methods
Introduction and Methodology has been described in the first
part of this article.
(QUOTE first article⁄ Ref. [1])
This second article focuses on recurrent/metastatic disease, sec-
ond primary tumors and squamous cell carcinoma metastatic tocervical nodes with an unknown primary site including categories
(C) 3, 4, 5 and 6.Results and discussion
C3. Evaluation of response after CRT (see Table 1)
Evaluation of response in head and neck after an organ-
preservation approach is crucial. Its complexity is based on three
main questions. The first question is when exactly we should
Table 1
Summary of Recommendations on the evaluation of response after non-surgical treatment.
Recommendation Phase Accepted consensus
(% of agreement)
Evaluation of response should be performed after the resolution of the inflammatory effect caused by concurrent chemo or
bioradiotherapy to avoid doubtful residual disease that could hinder decision-making and lead to unnecessary salvage surgery
1 YES (100)
Evaluation of response should be assessed at least 12 weeks (1 week variation is accepted) after completion of radiotherapy 1 YES (88)
Authors do not recommend the evaluation of response at 8 weeks
Evaluation of response should first be based on clinical assessment, followed by an imaging test (CT or MRI) according to each center
protocol, but always considering the initial imaging test (basal)
1 YES (88)
In case of suspected residual disease by CT/MRI, a PET/CT should be performed 2 YES
– Primary Tumor (76)
– Residual neck disease (71)
After conservative treatment, salvage surgery of the primary tumor is recommended if it was considered resectable at the initial staging.
In the absence of residual neck disease, neck dissection is not recommended
1 YES (72)
Planned neck dissection is not recommended in patients with N-positive disease (including N3) when complete response is achieved
after conservative treatment
2 YES (96)
If a complete response of the primary tumor is achieved, but there is evidence of residual neck disease, an elective neck dissection based
on the initial N stage is recommended. Radical neck dissection should be avoided
1 YES (90)
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depended on the optimal timing for neck dissection (ND) in case
of residual neck disease (RND), which is considered between 4
and 12 weeks after CRT to allow for resolution of acute effects
while preceding late fibrosis [2,3]. For many years, 8 weeks has
been taken as the optimal time to perform it, however, since de
introduction of PET/CT for the evaluation of response, most authors
and international guidelines recommend 12 weeks, to minimize
the rate of false positives caused by radiation-induced delayed
inflammatory changes [4]. In this regard, the experts agree that
response assessment should be performed after the resolution of
the inflammatory effect caused by radiation to avoid doubtful
residual disease that could lead to unnecessary salvage surgery.
The optimal recommended time is 12 weeks (1 week variation is
accepted) after completion of CRT. The second question is how to
assess the response after CRT. Although clinical assessment might
be unreliable, it is essential to evaluate symptoms and signs that
might indicate progression. Many studies have documented the
accuracy and high sensitivity of CT and MRI [2,3], however, their
specificity is low, especially to evaluate neck response, as not all
patients who undergo salvage surgery when RND is suspected by
CT evidence disease on pathologic examination [5]. In the last dec-
ade, retrospective studies evaluating the role of PET/CT have
reported high negative predictive values of 94.5–96.0% in patients
who have received CRT and bioradiotherapy, leading to a lower
number of NDs [6–8]. A recently published phase III trial evaluat-
ing the role of PET/CT confirmed these results [9]. In the light of
this evidence, NCCN guidelines recommend PET/CT at 12 weeks
as the new standard of care for the evaluation of response after
an organ-preserving approach [4]. However, CT and MRI are still
considered valid imaging techniques and are still the standard of
care in many institutions. In this regard, the authors of this consen-
sus agree that evaluation of response should first be based on clin-
ical assessment, followed by an imaging test (CT or MRI), according
to each center protocol, but always considering the initial imaging
test (basal). The authors did not reach consensus on whether PET/
CT should be the initial imaging test, however, they recommend its
use upfront of a FNA or ND when RND is suspected by CT.
The third question is what to do once having assessed the
response. Planned ND after an organ-preservation approach is still
debated. When nodal CR is achieved, no differences in recurrence
rates have been reported between planned ND and observation
[10–13]. ND entails considerable comorbidity, with a complication
rate of up to 35% [14,15]. Balancing the benefit with the increased
morbidity of post-CRT surgery, current evidence suggests that
ND should be limited to patients with RND after anorgan-preservation protocol [9]. International guidelines recom-
mend observation of patients who achieve CR after CRT. In case
of confirmed RND, selective neck dissection (SND) has become
widely accepted and is currently the procedure most frequently
used by head and neck surgeons. The authors reached consensus
in this regard, whereas after conservative treatment, salvage sur-
gery of the primary tumor is recommended if it was considered
resectable at initial staging and they do not recommend planned
ND in patients with N-positive disease (including N3) when CR is
achieved. In case of partial response of the primary tumor but no
evidence of RND, ND is not recommended either. Conversely, in
case of CR of the primary tumor but RND, an elective ND based
on the initial N stage is recommended. Radical ND should be
avoided, as it entails comorbidity without improvement of
survival.
C4. Recurrent/metastatic disease (see Table 2)
Most patients with HNSCC are diagnosed with locally advanced
disease whereas initial metastatic disease is rare [16]. Despite mul-
timodality therapy, 60% will develop locoregional or distant recur-
rence [17]. Most patients with recurrence and ineligible for salvage
therapy with radical intent, palliative systemic therapies remain
the only treatment option. However, some patients, especially
those with locoregional recurrence, might benefit from a radical
approach, as some series have reported prolonged survival in
patients amenable for salvage surgery or reirradiation [18–20]. In
oligometastatic disease, prolonged survival has also been reported
for patients with resected metachronous pulmonary metastases
[21]. Sacco et al. suggested that an aggressive approach removing
all known sites of disease might be beneficial for selected patients.
When surgery is not feasible, stereotactic radiotherapy (SBRT)
might be an alternative, although due to the lack of prospective tri-
als, this approach cannot be routinely recommended and should be
weighed against treatment-related toxicity [22]. Incomplete resec-
tions with positive margins are at high risk of recurrence, and reir-
radiation could entail high toxicity that must be balanced within
the potential clinical benefit [19]. Some authors have suggested
clinical factors that might predict the benefit of local therapies
[23]. The panel of experts suggests that all patients diagnosed with
HNSCC presenting local, regional or distant recurrence should be
evaluated by a multidisciplinary tumor board to decide the best
therapeutic approach, either radical or palliative. In the decision-
making process for patients with locoregional recurrence, patients’
general condition and comorbidities, localization and disease bur-
den, resectability (odds of achieving a R0/1 resection), time to
Table 2
Summary of recommendations for recurrent/metastatic disease.
Recommendation Phase Accepted consensus
(% of agreement)
All patients diagnosed with HNSCC presenting local, regional or distant recurrence should be evaluated by a multidisciplinary tumor
board to decide the best therapeutic approach, either radical or palliative
1 YES
(100)
To select the best therapeutic approach for patients with locoregional recurrence, the following factors should be considered: 1 YES
 Performance status (ECOG) (100)
 Comorbidities (92)
 Localization (96)
 Disease burden (84)
 Resectability (odds of achieving a R0/1 resection) (96)
 Time to progression/recurrence (92)
 Previous radiation field involving the actual recurrence (88)
To select the best therapeutic approach for patients with oligometastatic disease (including oligorecurrence), the following factors
should be considered:
2 YES
 Performance status (ECOG) (92)
 Comorbidities (84)
 Age (81)
 Status of locoregional disease in terms of response/remission, (100)
 Size and number of metastatic lesions (88)
 Localization (lung/other sites) (92)
 Previous treatments (88)
 Time to progression/recurrence. (88)
In patients diagnosed with oligometastatic disease amenable to radical treatment, all metastases should be treated either with surgery
or SBRT
1 YES
(96)
In patients with recurrent/metastatic (R/M) disease who are candidates for palliative systemic therapy, the following factors must be
considered:
1 YES
 Performance status (ECOG) (96)
 Comorbidities (96)
 Age (71)
 Weight loss (76)
 Previous systemic therapies for R/M or locoregional disease (84)(76)
Systemic therapies for patients with R/M disease: 1 YES
 In patients with ECOG 0–1 and no significant comorbidities, first-line chemotherapy should be based on the EXTREME regimen:
platinum plus FU in combination with cetuximab, followed by cetuximab until disease progression or unacceptable toxicity
(84)
 In patients who are platinum-refractory (recurrence or progression within the first 6-months after receiving cisplatin for locally-
advanced disease) weekly paclitaxel plus cetuximab followed by cetuximab until disease progression or unacceptable toxicity is the
regimen of choice
(68)
 In patients with ECOG 0–1 and no significant comorbidities that have progressed to a first-line platinum based chemotherapy,
weekly paclitaxel plus cetuximab followed by cetuximab until disease progression or unacceptable toxicity is the regimen of choice
(68)
 In patients with ECOG 2 or with significant comorbidities, best supportive care (which could include palliative radiation) is
recommended. Systemic chemotherapy is not recommended
(72)
* It should be noted that at the time this consensus was performed, data from Nivolumab had not yet been published and was
therefore not included as a treatment option to discuss in the study
All patients progressing to first-line cisplatin-based chemotherapy (regardless DFS and response to treatment) that preserve good
performance status, should be offered to participate in a clinical trial
1 (88)
A. Rueda et al. / Oral Oncology 70 (2017) 65–72 67recurrence, previous radiation involving the actual recurrence are
the main factors to be considered. Additionally, for oligometastatic
disease, status of locoregional disease in terms of response, size/
number of the metastatic lesions, localization (lung/other sites)
and previous treatments should also be considered.
Systemic therapy should be offered to patients who are not
amenable for a radical approach. Although survival outcomes are
poor, with a median progression-free survival (PFS) between 4
and 7 months and overall survival (OS) between 7 and 10 months
[24,25], selected patients might achieve long-term disease free sur-
vival (DFS)with palliative chemotherapy (CT). In this regard, several
clinical factors regarding patient status and disease burden can be
strong pretreatment predictors of outcome [26]. Elderly patients
can obtain the same benefit from systemic treatments compared
to younger patients, however at the expense of higher toxicity rates
[27,28]. Weight loss, malnutrition and comorbidities are well-
known negative prognostic factors in HNSCC [29,30]. Consequently,
the experts suggest that for patients with recurrent/metastatic
(R/M) disease, candidates for palliative systemic therapy, perfor-
mance status (ECOG), comorbidities, age, weight loss and previous
CT for R/M or locoregional disease should be considered.
Platinum is the most active agent in terms of response rates
(RR) and survival outcome. Palliative CT consists of a platinumdoublet, using 5-FU or taxanes. The addition of both agents
improves RR but not survival compared to monotherapy [31–33].
Cetuximab, a monoclonal antibody (MAb) directed against the epi-
dermal growth factor receptor, is the only targeted therapy to date
that has improved OS in combination with platinum/5FU in first-
line R/M HNSCC [25]. This regimen (EXTREME) is now the standard
of care for fit patients. It should be noted that in the subgroup anal-
ysis of the EXTREME trial, the survival advantage fell short of sta-
tistical significance in the elderly cohort (>65 years) compared to
younger adults and the entire intention-to-treat population [28].
In 2011, a non-randomized phase II trial evaluating paclitaxel in
combination with cetuximab in first-line treatment for R/M
patients unfit for cisplatin therapy showed a RR of 54% and an
improved OS, with a safe toxicity profile [34] whereas it might
be an alternative for patients unfit for a triplet. To date, agents used
in second-line therapy for R/M HNSCC, including methotrexate,
taxanes or cetuximab, have a low RR and none have shown survival
benefit. Nivolumab, an anti–programmed death 1 (PD-1) mono-
clonal antibody, is the first drug that has recently shown improved
OS compared with single-agent chemotherapy or cetuximab in a
phase III randomized trial for platinum-refractory R/M SCCHN [35].
The experts recommend the EXTREME regimen as first-line CT
for fit patients, without significant comorbidities and ECOG 0–1.
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within the first 6-months after receiving cisplatin for locally-
advanced disease) or have progressed to a first-line platinum-
based CT, weekly paclitaxel plus cetuximab until disease progres-
sion or unacceptable toxicity is recommended. Patients with signif-
icant comorbidities or ECOG2 should be offered best supportive
care (which might include palliative radiation). In the light of
recent results, nivolumab should be the treatment of choice in
patients progressing to a platinum-based CT, when clinically avail-
able. Cetuximab as single agent is an acceptable alternative for
patients who are neither amenable to receive paclitaxel nor nivo-
lumab. All patients progressing to first-line CT with ECOG 0–1
should be offered to participate in a clinical trial.
It should be noted that at the time this consensus was per-
formed, data on nivolumab had not yet been published and was
therefore not included as a treatment option in the first 2 phases
of the study.
C5. Management of second primary tumors (see Table 3)
Patients with HNSCC are at high risk of developing second pri-
mary tumors (SPT). SPT are defined as metachronous invasive solid
cancer developing 6 months after an index HNSCC, under the cri-
teria of Warren and Gates and modified by the National Cancer
Institute (NCI) [36,37]. Their incidence is high, from 5% to 12% at
5 years, representing the leading long-term cause of death in
patients with HNSCC, tripling the number of deaths caused by dis-
tant metastases [38,39]. In addition, patients with a SPT have an
increased risk for developing subsequent primary tumors: this risk
remains constant through follow-up, and survival decreases pro-
gressively with the development of every new head and neck
tumor [38,40,41]. Most common sites of SPT are the head and neck
region, lung and esophagus. The risk and distribution of SPT differ
significantly according to the subsite of the index cancer [42]:
hypopharynx and oropharynx carried the highest excess risk of
SPT, but during the HPV era, risk associated with oropharynx can-
cer declined; the head and neck region is the most common site
when the index tumor is in the oral cavity or oropharynx, while
hypopharynx and larynx tumors are frequently associated to SPT
in the lung [42]. Therefore, the panel recommends the definition
of SPT according to Warren and Gates Criteria and agrees that
patients should be followed up for a minimum of 10 years, whichTable 3
Summary of recommendations on second primary tumors (SPT).
Recommendation
The definition of SPT must be based on Warren and Gates Criteria:
Due to the high incidence of SPT, patients should be followed-up for a minimum of 1
Chest X-rays are considered insufficient to detect and diagnose a SPT in the lung dur
PET/CT is recommended as part of the initial study for all patients with a treated inde
head and neck, lung or esophagus.
To select the best therapeutic approach for patients diagnosed with a SPT, the follow
 Patient’s general condition and comorbidities.
 Previous treatments received
 Localization of the second primary
Treatment recommendations for SPT:
 CRT is the recommended treatment for patients with high burden SPT (60 mm3 or
 Neck dissection and/or neck radiation of areas previously treated within the index
with N0 SPT
 Reirradiation must always be considered in all patients presenting SPT of head a
 CRT is recommended over bioradiotherapy in patients diagnosed with non-surgic
 CRT is recommended over surgery for SPT located in the oropharynx
 Total glossectomy plus total laryngectomy is not recommended in patients withcould be extended in patients with a history of alcohol and smok-
ing abuse.
SPT located in the head and neck can be detected during follow-
up by fiberoptic endoscopy, CT or MRI imaging, which are the rou-
tinely recommended tests. However, there is no consensus in the
literature regarding which imaging technique is the most appropri-
ate for the detection of second primary malignances in the lung.
The NCCN guidelines for HNSCC based on Lung Cancer NCCN
guidelines recommend the use of low-dose computed tomography
(LDCT) of the chest to screen selected patients at high risk of lung
cancer, since chest X-rays are not recommended for lung cancer
screening [43–45]. The authors agree that chest X-rays are insuffi-
cient for the detection of SPT in the lung. However, as LDCT has not
been approved by the Spanish National Public Health System, no
consensus was reached on its recommendation. As reported by
Hearle and col. [46], when a SPT has been diagnosed, PET/CT might
to be useful to detect other synchronous tumors and to rule out
metastasis. Therefore, the experts recommend a PET/CT as part of
the initial staging.
No level 1 evidence exists regarding the best treatment
approach for patients with a previously treated HNSCC diagnosed
with a SPT. Treatment options usually include surgery, CT and reir-
radiation with the aim of improving local control, quality of life
and survival. It is important to select patients that could benefit
from a treatment, either radical or palliative. Age, general condi-
tion and comorbidities, as well as late toxicity from previous treat-
ments are to be considered, as these patients might be at risk of
developing complications. SPT localization and previous treatment
are crucial to decide whether they are eligible for radical or pallia-
tive therapy. The authors recommend considering these factors to
select the best therapeutic approach in this scenario.
As mentioned, whenever possible, surgery and reirradiation are
both treatments to be considered upfront. When feasible, surgery
in early stage SPT is also recommended, with studies indicating a
5-year survival rate of 35% in radically resected SPTs (11% for lung
metastases) [47,48]. It should also be noted that some patients
could benefit from limited resections, as some authors have sug-
gested that early-stage SPT in head and neck without nodal
involvement could avoid ND [49]. Reirradiation might achieve
favorable outcomes, but must be well balanced against toxicity
[50,51], however, as mentioned, the treatment approach could
change depending on the location. In non-radiated patients, RT orPhase Accepted consensus
(% of agreement)
2 YES
(76)
0 years 1 YES
(71)
ing follow-up 2 YES
(84)
x HNSCC and diagnosed with a SPT located in the 1 YES
(84)
ing factors should be considered: 1 YES
(100)
2 YES
greater) that have not been previously irradiated (76)
tumor should be avoided in patients diagnosed (84)
nd neck (72)
al SPT (71)
(72)
locally advanced recurrent oropharyngeal cancer (72)
A. Rueda et al. / Oral Oncology 70 (2017) 65–72 69CRT is preferred for SPT in the oropharynx, as resection might
entail loss of organ function and high comorbidity. The same
should apply in patients with high burden disease that imply muti-
lating surgeries. Surgery might represent the only option in previ-
ously radiated patients, but it should be balanced with the risk of
surgical complications. The experts suggest several specific recom-
mendations for the treatment of SPT that are shown in Table 3.
C6. Squamous cell carcinoma of unknown primary of the head and
neck (SCCUP) (see Table 4)
SCCUP is defined as metastatic disease in the cervical lymph
nodes without any evidence of a primary tumor in the upper
aerodigestive tract after appropriate investigation [4,52]. It repre-
sents approximately 1–4% of all cancers of the head and neck
[53] and must be a diagnosis of exclusion, as increasingly imaging
and biopsy techniques have limited the number of patients in
whom SCCUP is diagnosed. Tissue confirmation is mandatory.
Cytology obtained by a FNA is preferred over an open biopsy, as
the latter could cause disruption of fascial planes that act as a nat-
ural barrier to tumoral spread [54]. Cross-sectional imaging of the
neck such as contrast-enhanced CT and/or MRI and the availability
of fiberoptic endoscopy has changed the detection of small primary
cancers, and have shown to increase the rates of detection of
tumors not found by physical examination, but with suggestive
anatomic images [55]. The panel agree to define SCCUP as the pres-
ence of SCC metastasis in any cervical lymph node confirmed by
FNA or core needle biopsy, with or without concomitant supraclav-Table 4
Summary of recommendations for squamous cell carcinoma of unknown primary of the h
Recommendation
Squamous cell carcinoma (SCC) of unknown primary of the head and neck (SCCUP) is
cervical lymph node confirmed by cytology or core needle biopsy, with or withou
without any evidence of a primary tumor of the upper aerodigestive tract, after an
thorough physical examination (particularly of the oral cavity and skin), a proper
endoscopy performed by a qualified specialist
The authors do not recommend performing an excisional biopsy of metastatic lymph
diagnosis
Complete diagnosis of SCCUP should include:
 PET/CT
 Direct laryngoscopy under general anesthesia (exploring nasopharynx, oropharyn
 HPV determination detected from a FNA specimen using IHC or PCR
 EBV determination detected from a FNA specimen using IHC or PCR
Regarding direct laryngoscopy:
 Directed biopsy of the suspected mucosal areas is recommended
 Routinely lingual tonsillectomy is not recommended
 There was no consensus on whether randomized base of tongue biopsies, unilate
recommended
 In case of p16 or DNA-HPV positive lymph nodes, the approach should be discus
The primary goals of SCCUP treatment are to achieve control of the neck disease bur
Regarding the treatment of N1-N2b disease;
 Surgery (Ipsilateral neck dissection) is recommended
 Adjuvant RT is indicated when:
 pN2b
 Perineural invasion and/or perivascular invasion
 Adjuvant CRT is indicated when:
 Extranodal spread
 Soft tissue infiltration
 Recommended regimen for Concurrent CT is cisplatin at a dose of 100 mg/m2 on
 Adjuvant RT should involve suspected mucosal subsets based on initial diagnosis
Treatment of N2c-N3 disease;
 Concurrent CRT is recommended as treatment of choice. Salvage ND should be off
evaluation of response
 ICT followed by concurrent CRT is recommended as an alternative option to CRT.
residual neck disease at the evaluation of response
 ICT followed by surgery and adjuvant RT is not recommended
 Recommended CT regimen for ICT is cisplatin-5-fluoracil-Docetaxel
 Evaluation of response should be assessed 8–12 weeks after CRTicular metastatic nodes, without any evidence of a primary tumor
of the upper aerodigestive tract, after an appropriate investigation
that must include a thorough physical examination, a proper imag-
ing test (CT or MRI) and a fiberoptic endoscopy performed by a
qualified specialist. Excisional biopsy of the metastatic lymph
nodes before having carried out a complete diagnosis is not
recommended.
In patients diagnosed with SCCUP, PET or PET/CT has proven
useful to detect up to 30% of primary mucosal tumors that had
not previously been detected by CT/MRI [56] and to rule out dis-
tant metastases. However, due to a 10% to 20% rate of false posi-
tives, findings should be confirmed by biopsy, by direct pan-
endoscopy under general anesthesia. In the event preprocedural
findings do not suggest potential biopsy targets, direct pan-
endoscopy should explore the following locations: nasopharynx,
oropharynx, larynx, hypopharynx and upper esophagus; Directed
biopsy of the suspected mucosal areas is recommended in all head
and neck guidelines. As nasopharyngeal and oropharyngeal carci-
nomamight be caused by EBV and HPV infection respectively, their
determination from FNA samples is recommended in all patients
diagnosed with SCCUP. Recent studies suggest that an increasing
proportion of SCCUP are associated with HPV at a rate similar to
that of primary oropharyngeal cancer [57,58]. Directed biopsies
might also be driven by node levels involved. Ipsilateral tonsillec-
tomy rather than deep tonsil biopsy is frequently performed in the
initial evaluation of a patient with SCCUP, as tonsils and base of the
tongue are the most common sites for small primary tumors ini-
tially thought to represent SCCUP [55,59]. Moreover, p16 oread and neck (SCCUP).
Phase Accepted consensus
(% of agreement)
defined as the presence of SCC metastases in any
t concomitant supraclavicular metastatic nodes,
appropriate investigation that must include a
imaging test (CT or MRI) and a fiberoptic
1 YES
(84)
nodes before having carried out a complete 1 YES
(88)
1 YES
(100)
x, larynx, hypopharynx and upper esophagus) (84)
(84)
(72)
1 YES
(90)
(72)
ral or bilateral palatine tonsillectomy should be NO CONSENSUS
sed in a multidisciplinary tumor board YES
den and prevent mucosal emergence 1 YES
(96)
1 YES
(88)
(96)
(92)
days 1, 22, 43 during RT
(93)
2 YES
ered in patients with residual neck disease at the (80)
Salvage ND should be offered in patients with (76)
NO
(80)
(84)
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most common site for a primary tumor, although other primary
tumors with involved lymph nodes above the clavicles may also
stain for the p16 protein [60]. Conversely, contralateral tonsillec-
tomy is widely discussed: some authors justify this procedure as
there are studies reporting the contralateral spread of occult tonsil
cancer and the presentation of synchronous bilateral tonsil cancer
[61,62], however rates are low and evidence of contralateral pro-
gression rare after surgery for known primary T1 tonsil cancer
[63]. Diagnostic tonsillectomy is not considered a standard proce-
dure in some institutions: most data comes from the US, where
HPV-related tumors are more frequent, but in areas like Europe,
most tumors are caused by smoking and alcohol abuse. Conse-
quently, and because PET/CT might rule out tumors in that area,
some authors considered tonsillectomy unnecessary in the absence
of suspected mucosal findings. The panel of experts agree that
complete diagnosis of SCCUP should include a PET/CT, a direct
pan-endoscopy under general anesthesia (exploring nasopharynx,
oropharynx, larynx, hypopharynx and upper esophagus) and HPV
and EBV determination (detected from a FNA specimen using IHC
or PCR) [58]. During direct pan-endoscopy, a direct biopsy of the
suspected mucosal areas is recommended. Routinely lingual tonsil-
lectomy is not recommended, and there was no consensus on
whether randomized base of tongue biopsies, unilateral or bilateral
palatine tonsillectomy should be recommended. However, in case
of p16 or DNA-HPV positive lymph nodes, this approach should
be discussed in a multidisciplinary tumor board.
Treatment of SCCUP often requires multimodality therapy. Due
to its low prevalence, prospective randomized trials are lacking
and treatment recommendations are based on large retrospective
series and extrapolated data from studies including HNSCC with
a known primary. The experts agree that the primary goals of the
treatment are achieving control of the neck disease burden and
preventing mucosal emergence. Treatment will depend on nodal
stage. N1 is rare and usually has good prognosis, so generally
single-modality therapy is acceptable, as patients do well either
with RT or with surgery alone, and ipsilateral neck recurrence
and mucosal progression rates range between 10% and 20%
[60,64]. N2a and N2b are common presentations of SCCUP, which
are usually managed with surgery followed by RT or CRT. N2a
treatment can vary depending on patients’ risk factors and the
presence of adverse pathological factors. p16 positive patients with
no smoking history could be treated with either surgery or RT
alone, assuming that the oropharynx would be the most common
primary site and that they might have better prognosis compared
to p16-negative patients. [65,66]. N2a and N2b disease with extra-
nodal spread usually receive adjuvant CRT as extrapolated from
prospective studies, although it must be considered that these
did not include patients with SCCUP and only a few presented
oropharyngeal cancer [67,68]. The same rule applies when adju-
vant RT is given in presence of minor adverse features (perivascu-
lar and perineural invasion) [68]. Some authors recommend
concurrent CRT in patients with clinical or radiological extranodal
spread to save ND, assuming they would further receive adjuvant
CRT [52]. N2c-N3 disease has higher rates of regional and distant
recurrence when treated with surgery alone [53,63]. Surgery fol-
lowed by postoperative RT/CRT has similar results to radical CRT,
although its use has been extrapolated from trials in locally-
advanced HNSCC [69–74]. CRT is generally preferred to leave sur-
gery as a salvage therapy. Regarding RT treatment, IMRT is the
modality of choice as it allows tissue-sparing and preserves sali-
vary glands. Radiation of mucosal subsets and the contralateral
neck is the standard of care at most institutions as it reduces muco-
sal emergence and contralateral failure, although its use has
reported increased toxicity [71,75–78]. Most commonmucosal tar-
gets include oropharynx and nasopharynx, as up to 80% of SCCUPusually present level 2 and 3 neck disease [52]. The absence of level
2 nodes indicates a higher probability of a supraglottic or hypopha-
ryngeal primary tumor. Recommendations from the panel of
experts regarding treatment of SCCUP are exhibited in Table 4.Conclusions
HNSCC treatment is complex and its management challenging.
It requires the work and expertise of all specialists involved. This
consensus using the Delphi methodology has been developed as
an educational tool to be used by all head and neck professionals
in their daily practice to achieve the best outcome and care for
head and neck cancer patients.Disclosures
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